8-K: Indaptus: Mixed Clinical Trial Results, $5.7M Capital Raise

Indaptus Therapeutics announced mixed clinical trial updates for its INDP-D101 study, including a transient partial response and disease progression in early combination therapy, alongside a $5.7 million capital raise.

Summary

• Completed the monotherapy portion of the INDP-D101 clinical trial.
• Initiated seven patients in the initial cohort of combination therapy with tislelizumab, BeOne's anti-PD-1 monoclonal antibody.
• One patient in the monotherapy study, who previously received anti-PD-1 therapy for urothelial cancer with liver metastases, showed a clear reduction in liver metastases size, consistent with a Partial Response.
• This patient subsequently experienced disease progression at the next scheduled imaging and discontinued the study, though the investigator noted clinical benefit over a 4-month period.
• Of the first three evaluable patients in the combination therapy cohort, one patient had stable disease, and the other two patients had disease progression.
• Raised approximately $5.7 million in gross proceeds through the sale of convertible promissory notes and accompanying warrants.
• In July 2025, the convertible notes were converted into common stock and pre-funded warrants, strengthening the company's balance sheet.

Sentiment

Score: 4

Explanation: The filing presents mixed clinical results, with an initial partial response that was not sustained and disease progression in a majority of early combination therapy patients. While the capital raise is positive for the balance sheet, the clinical efficacy data is not overwhelmingly positive at this early stage, leading to a cautious sentiment.

Positives

• Monotherapy demonstrated a Partial Response in one patient with advanced urothelial cancer and liver metastases, indicating potential clinical benefit.
• Successfully raised approximately $5.7 million in gross proceeds, enhancing the company's financial position.
• The conversion of convertible notes into common stock and pre-funded warrants in July 2025 strengthened the balance sheet.
• Progressed to the combination therapy cohort, with seven patients already dosed.

Negatives

• The patient who achieved a Partial Response in monotherapy subsequently experienced disease progression and discontinued the study.
• Two out of three evaluable patients in the initial combination therapy cohort showed disease progression.
• Only one patient in the initial combination therapy cohort achieved stable disease.

Risks

• Limited operating history.
• Conditions and events that raise substantial doubt regarding the ability to continue as a going concern.
• Need for, and ability to raise, additional capital given a lack of current cash flow.
• Clinical and preclinical development involves a lengthy and expensive process with an uncertain outcome.
• Incurrence of significant research and development expenses and other operating expenses, which may make it difficult to attain profitability.
• Pursuit of a limited number of research programs, product candidates, and specific indications, risking failure to capitalize on product candidates or indications that may be more profitable or have a greater likelihood of success.
• Ability to obtain and maintain regulatory approval of any product candidate.
• Market acceptance of product candidates.
• Reliance on third parties to conduct preclinical studies and clinical trials and perform other tasks.
• Reliance on third parties for the manufacture of product candidates during clinical development.
• Ability to successfully commercialize Decoy20 or any future product candidates.
• Ability to obtain or maintain coverage and adequate reimbursement for products.
• Impact of legislation and healthcare reform measures on the ability to obtain marketing approval for and commercialize Decoy20 and any future product candidates.
• Product candidates of competitors that may be approved faster, marketed more effectively, and better tolerated than company's product candidates.
• Ability to adequately protect proprietary or licensed technology in the marketplace.
• Impact of, and costs of complying with, healthcare laws and regulations, and failure to comply with such laws and regulations.
• Information technology system failures, cyberattacks, or deficiencies in cybersecurity.
• Unfavorable global economic conditions.

Future Outlook

The company continues to progress its Decoy platform in the clinic to better understand its potential as a breakthrough therapy in combination with BeOne's tislelizumab. Management anticipates sharing initial combination trial data later this year and remains focused on disciplined execution.

Management Comments

• "We currently have completed the monotherapy portion of our trial and have initiated seven patients in our initial cohort of combination therapy with tislelizumab, BeOne's anti PD-1 monoclonal antibody." Dr. Roger Waltzman, Chief Medical Officer.
• "We are encouraged to report a patient in our monotherapy study who previously received an anti-PD-1 therapy had a clear reduction in size of liver metastases, consistent with a Partial Response. Unfortunately, there was evidence of disease progression at the next scheduled imaging and the patient discontinued the study." Dr. Roger Waltzman, Chief Medical Officer.
• "However, the investigator believes the therapy provided clinical benefit for the patient over that 4-month period." Dr. Roger Waltzman, Chief Medical Officer.
• "Additionally, we have dosed 7 patients in the combination therapy initial safety cohort. Of the first three evaluable patients, one patient had stable disease at the first assessment, and the other two patients had disease progression. We continue to dose additional patients and will report their results in the coming weeks." Dr. Roger Waltzman, Chief Medical Officer.
• "We continue to progress our Decoy platform in the clinic to better understand this potential breakthrough therapy in combination with BeOne's tislelizumab." Jeffrey Meckler, Chief Executive Officer.
• "On the financial front, we raised approximately $5.7 million in gross proceeds through the sale of convertible promissory notes and accompanying warrants. In July 2025, the notes were converted into common stock and pre-funded warrants, which strengthens our balance sheet." Jeffrey Meckler, Chief Executive Officer.
• "We remain focused on disciplined execution and look forward to sharing initial combination trial data later this year." Jeffrey Meckler, Chief Executive Officer.

Industry Context

The biotechnology industry, particularly oncology, heavily relies on clinical trial success and combination therapies. The use of PD-1 inhibitors like tislelizumab in combination with novel immunotherapies is a common strategy to enhance efficacy and overcome resistance. Indaptus's Decoy platform, targeting multiple immune receptors (TLR, NOD-like, STING), represents an antigen-agnostic approach, which could differentiate it from more targeted therapies if successful. The mixed results in early-stage trials are typical for the high-risk, high-reward nature of drug development in this sector.

Comparison to Industry Standards

• Early-stage clinical trial results, especially in oncology, often show mixed responses, with partial responses and stable disease being positive indicators, even if not sustained. For example, in Phase 1 trials for novel cancer immunotherapies, a partial response rate of 10-20% can be considered promising enough to advance to further stages, depending on the patient population and prior treatments.
• The observation of a Partial Response in a patient with advanced urothelial cancer and liver metastases who previously failed anti-PD-1 therapy is notable, as this represents a difficult-to-treat population. For instance, in similar late-line settings, single-agent activity is often limited, making any response significant.
• The disease progression in two out of three evaluable patients in the combination arm is not uncommon for initial safety cohorts, where dose escalation and patient selection are still being optimized. Comparisons to other early-stage combination trials, such as those combining checkpoint inhibitors with oncolytic viruses or other immune modulators, often show similar variability in initial responses.
• The capital raise of $5.7 million is a modest amount for a clinical-stage biotech, but its conversion to equity strengthens the balance sheet, which is a positive for financial stability in an industry known for high cash burn.

Stakeholder Impact

• Shareholders: Potential for volatility due to mixed clinical trial results. The capital raise strengthens the balance sheet, which could be seen as a positive for financial stability, but the conversion of notes to common stock and warrants could imply dilution.
• Patients: The therapy showed a transient clinical benefit in one patient, offering a glimmer of hope, but also the reality of disease progression. Continued trial progress is crucial for future treatment options.
• Employees: Continued progress in clinical trials and a strengthened balance sheet provide some stability for ongoing operations.
• Creditors: The conversion of convertible notes to equity reduces debt, which is positive for creditors.

Next Steps

• Continue dosing additional patients in the combination therapy cohort.
• Report results from additional patients in the coming weeks.
• Share initial combination trial data later this year.

Key Dates

Recommendation

The clinical update presents a mixed bag of results. While a Partial Response in a difficult-to-treat patient population is encouraging, its lack of durability and the progression seen in other patients in the early combination cohort temper enthusiasm. The successful capital raise strengthens the balance sheet, providing runway for continued development. Given the early stage of the trial and the high-risk nature of biotech, a 'hold' recommendation is appropriate, awaiting more comprehensive and durable efficacy data from the ongoing combination study later this year before making a more definitive investment decision.

Keywords

Indaptus Therapeutics, INDP, biotechnology, cancer treatment, viral infection treatment, INDP-D101, clinical trial, Decoy20, monotherapy, combination therapy, tislelizumab, PD-1 inhibitor, urothelial cancer, liver metastases, Partial Response, stable disease, disease progression, capital raise, convertible notes, warrants, balance sheet, immunotherapy, Toll-like receptor, TLR, NOD-like receptor, NLR, STING agonist, pre-clinical models, hepatitis B virus, HBV, human immunodeficiency virus, HIV